Ekso Bionics Holdings, Inc. (EKSO) Insider Sells $175,500.00 in Stock
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) insider Russ Angold sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total transaction of $175,500.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Ekso Bionics Holdings, Inc. (EKSO) traded up $0.19 during mid-day trading on Monday, reaching $3.07. 5,309,117 shares of the company’s stock traded hands, compared to its average volume of 878,484. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.09 and a quick ratio of 5.73. Ekso Bionics Holdings, Inc. has a 12-month low of $0.99 and a 12-month high of $4.90.
Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Wednesday, November 8th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Ekso Bionics had a negative net margin of 343.53% and a negative return on equity of 323.00%. The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.40 million. equities research analysts predict that Ekso Bionics Holdings, Inc. will post -0.81 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in the company. National Planning Corp grew its position in shares of Ekso Bionics by 122.2% during the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock worth $620,000 after acquiring an additional 286,492 shares during the last quarter. Carl Domino Inc grew its position in shares of Ekso Bionics by 125.2% during the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock worth $224,000 after acquiring an additional 102,734 shares during the last quarter. Intellectus Partners LLC grew its position in shares of Ekso Bionics by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after acquiring an additional 5,294 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Ekso Bionics by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after acquiring an additional 176,197 shares during the last quarter. Institutional investors and hedge funds own 2.87% of the company’s stock.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.